Lede: Stanford University researchers tracked 30 US special operations veterans who received ibogaine at a Tijuana clinic, documenting sustained PTSD score drops post-treatment. Paragraph 1: Primary data from the BBC-reported cohort showed participants dosed at up to 14 mg/kg experienced 72-hour sessions with self-reported memory reprocessing; Kfoury case cited pre/post military trauma history and failed prior interventions (BBC, 2024). Paragraph 2: Cross-referenced with the 2024 Stanford observational study (Williams et al., Nature Medicine), ibogaine linked to rapid TBI/PTSD improvements in 18 veterans at 1-month follow-up via CAPS-5 metrics; earlier Lotsof 1962 observations on opioid withdrawal cited as mechanistic precursor (Williams et al., 2024). Paragraph 3: Bouso pharmacodynamic reviews note unresolved separation of hallucinogenic versus alkaloid effects, with no large-scale RCTs yet; Mexican unregulated setting limits generalizability per existing trial registries (Bouso et al., 2023 review).